Marc D. Kozin - 10 Aug 2021 Form 4 Insider Report for Dicerna Pharmaceuticals Inc

Role: Director
Signature: /s/ Douglas W. Pagan, attorney-in-fact
Issuer symbol: N/A
Transactions as of: 10 Aug 2021
Net transactions value: +$70,986
Form type: 4
Filing time: 10 Aug 2021, 18:44:44 UTC
Previous filing: 11 Jun 2021
Next filing: 10 Sep 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DRNA	Common Stock	Purchase	$70,986	+3,000	+90%	$23.66	6,333	10 Aug 2021	Direct	F1
holding	DRNA	Common Stock						5,000	10 Aug 2021	By Marc D. Kozin Revocable Trust

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $23.455 to $23.840, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.

Content

The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $23.455 to $23.840, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.